RIZE — Rize Oncology Share Price
Last trade - 00:00- CA$1.51m
- -CA$0.09m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.99 | ||
| Price to Tang. Book | 0.99 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -53.11% | ||
| Return on Equity | -44.4% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rize Oncology Inc., formerly GeneTether Therapeutics Inc., is a pharmaceutical company engaged in developing oncology therapies. The Company is focused on advancing treatments for soft tissue sarcoma. It is developing STS-201 for the treatment of soft tissue sarcoma. STS-201 is a small-molecule drug candidate that has exhibited significant utility in soft tissue sarcoma, as well as other types of cancers and certain proliferative diseases.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 13th, 2021
- Public Since
- March 28th, 2022
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 75,744,674
- Address
- c/o Pushor Mitchell LLP, KELOWNA, V1Y 2B3
- Web
- https://rizeoncology.com/
- Phone
- +1 2508691195
- Auditors
- Dale Matheson Carr-Hilton LaBonte LLP
Similar to RIZE
1933 Industries
Canadian Securities Exchange
1CM
Canadian Securities Exchange
Adastra Holdings
Canadian Securities Exchange
Aion Therapeutic
Canadian Securities Exchange
Asia Green Biotechnology
Canadian Securities Exchange
FAQ
As of Today at 22:58 UTC, shares in Rize Oncology are trading at CA$0.02. This share price information is delayed by 15 minutes.
Shares in Rize Oncology last closed at CA$0.02 and the price had moved by -55.56% over the past 365 days. In terms of relative price strength the Rize Oncology share price has underperformed the Toronto Stock Exchange 300 Composite Index by -61.03% over the past year.
There is no consensus recommendation for this security.
Find out moreRize Oncology does not currently pay a dividend.
Rize Oncology does not currently pay a dividend.
Rize Oncology does not currently pay a dividend.
To buy shares in Rize Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.02, shares in Rize Oncology had a market capitalisation of CA$1.51m.
Here are the trading details for Rize Oncology:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: RIZE
Based on an overall assessment of its quality, value and momentum Rize Oncology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rize Oncology. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -22.48%.
As of the last closing price of CA$0.02, shares in Rize Oncology were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rize Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Rize Oncology's directors